Neuromedin B

What is Neuromedin B?

Neuromedin B (NMB) is a 10-amino-acid C-terminally amidated peptide and the second mammalian member of the bombesin peptide family — the family named for bombesin, the prototype 14-residue peptide originally isolated from the skin of the European frog Bombina bombina by Erspamer and colleagues in the 1970s. NMB was isolated from porcine spinal cord in 1983 by Naoto Minamino, Kenji Kangawa, and Hisayuki Matsuo at the National Cardiovascular Center Research Institute in Osaka — the same laboratory that produced atrial natriuretic peptide, brain natriuretic peptide, neuromedin U, and (later) ghrelin. The mature peptide sequence is Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2; the C-terminal His-Phe-Met-NH2 is the bombesin-family signature pharmacophore shared with the longer mammalian bombesin homolog gastrin-releasing peptide (GRP). NMB is encoded by the NMB gene on human chromosome 15q25 (cloned and characterized by Krane, Naylor, Helin-Davis, Chin, and Spindel in 1988 J Biol Chem) and is processed from a 76-residue prepro-NMB precursor. It signals primarily through the neuromedin B receptor (NMBR, also designated bombesin receptor subtype 1 or BB1), a Gq-coupled G-protein-coupled receptor cloned in 1991 by Wada, Way, Lebacq-Verheyden, and Battey from rat brain and shown to have higher affinity for NMB than for GRP — the inverse selectivity of GRPR (BB2), which prefers GRP. The third member of the receptor family, BRS-3 (BB3), is an orphan receptor with low affinity for both NMB and GRP. The 2008 Jensen, Battey, Spindel, and Benya IUPHAR review consolidated the modern nomenclature and pharmacology of the mammalian bombesin receptor family. Functionally, NMB has documented roles across multiple physiological systems: smooth-muscle contraction (gut, uterus), thyroid TSH inhibition (a bombesin-family signature, with the 2006 Oliveira et al. paper showing dysregulated pituitary-thyroid axis in NMBR knockout mice), thermoregulation (NMB is hypothermic when administered centrally), satiety, anxiety modulation, and pain and itch processing. The 2012 Fleming, Saxena, Goldbach-Mansky paper established that NMB is highly expressed in pain- and itch-sensing somatosensory neurons of the dorsal spinal cord, distinguishing it from GRP, which is the dominant bombesin-family pruritogen in the spinal cord. Drug development has focused on bombesin-receptor antagonists for small-cell lung cancer (which expresses bombesin receptors as autocrine growth-factor receptors) and on selective NMBR ligands for psychiatric and dermatological indications, but no NMB or NMBR-targeted therapeutic has reached approval as of 2026.

What Neuromedin B Is Investigated For

NMB is an endogenous-biology and drug-target topic, not a peptide consumers take. Its scientific footprint sits within the broader bombesin-family pharmacology, alongside gastrin-releasing peptide (GRP) and the orphan BRS-3 receptor. The receptor pharmacology is the central organizing axis: NMBR (BB1) prefers NMB, GRPR (BB2) prefers GRP, and BRS-3 has low affinity for both — the IUPHAR nomenclature and pharmacology was consolidated by Jensen, Battey, Spindel, and Benya in 2008. The functional biology spans multiple physiological systems. Smooth-muscle contraction (gut, uterus, urinary bladder) is the classical bombesin-family activity. Endocrine effects on the pituitary-thyroid axis are well-documented — Oliveira and colleagues showed in 2006 that NMBR knockout mice have dysregulated TSH secretion, establishing NMB as a hypothalamic regulator of thyroid function. Anxiety and stress phenotypes have been characterized in NMBR knockout mice (Yamada 2002, 2003) showing impaired inhibitory avoidance learning under stress and altered emotional behavior. Spinal cord pain and itch processing was developed by the 2012 Fleming et al. paper showing high NMB expression in pain- and itch-sensing somatosensory neurons of the dorsal horn. Cancer drug development has been an active translational arm — bombesin receptors (particularly GRPR) are expressed on small-cell lung cancer and other tumors as autocrine growth-factor receptors, and bombesin-receptor antagonists (and radiolabeled bombesin analogs for theranostic imaging and therapy in prostate and other cancers) have been pursued for decades. The 2007 Kelly et al. JNCI paper reported on a clinical anti-bombesin-pathway antibody for SCLC, with subsequent development of small-molecule and peptide receptor antagonists. Despite the breadth of preclinical biology, no NMB-specific therapeutic has reached approval, and the broader bombesin-receptor antagonist class has produced limited clinical wins outside of the radiolabeled-imaging-agent space. The honest framing is that NMB is foundational endogenous-peptide biology with a clearly defined receptor (NMBR) and a diverse action profile, but the clinical chapter is incomplete.

History & Discovery

Neuromedin B was isolated in 1983 by Naoto Minamino, Kenji Kangawa, and Hisayuki Matsuo at the National Cardiovascular Center Research Institute in Osaka, Japan — the same laboratory that produced atrial natriuretic peptide (1984), brain natriuretic peptide (1988), neuromedin U (1985), and ghrelin (1999). The 1983 Biochem Biophys Res Commun paper reported the isolation of a novel 10-amino-acid amidated peptide from porcine spinal cord that the authors recognized as a mammalian member of the bombesin family. The naming convention 'neuromedin' (used for both NMB and the slightly later NMU) reflects the team's strategy of systematically identifying bioactive peptides from neural tissue extracts; the 'B' denotes the second peptide of the series after NMA (an earlier-isolated bombesin-related peptide that was eventually recognized as a fragment). The bombesin-family context for NMB was already established. Bombesin itself had been isolated from the skin of the European fire-bellied frog Bombina bombina by Vittorio Erspamer and colleagues in the 1970s and was already a major research peptide in gastrointestinal physiology. The 1979 isolation of gastrin-releasing peptide (GRP) by McDonald, Jornvall, Nilsson, Vagne, Ghatei, Bloom, and Mutt at the Karolinska Institute had established the mammalian bombesin homolog. NMB joined GRP as the second mammalian bombesin-family peptide, with the two peptides having distinct lengths (10 vs 27 residues), distinct tissue distributions, and distinct receptor preferences. The receptor pharmacology was completed in 1991 by Wada, Way, Lebacq-Verheyden, and Battey at the National Institutes of Health, who cloned the rat NMBR (initially called the 'neuromedin-B-preferring bombesin receptor' or BB1) and showed its preferential affinity for NMB over GRP — establishing the receptor-pharmacology framework that has organized the bombesin-family literature since. The complementary GRPR (BB2) had been cloned the previous year. The orphan BRS-3 (BB3) was identified later. The 2008 Jensen, Battey, Spindel, and Benya IUPHAR review provided the consolidated contemporary nomenclature and pharmacology for the three-receptor mammalian bombesin family. The physiological roles of NMB were developed across the 1990s and 2000s through pharmacology and knockout-mouse genetics. Smooth-muscle contraction (the classical bombesin-family activity) was characterized in early biochemistry. The pituitary-thyroid-axis role was established by Oliveira, Costa, and colleagues (2006 J Mol Endocrinol) showing that NMBR knockout mice have dysregulated TSH secretion. The anxiety and stress phenotypes were developed by Yamada and colleagues (2002 Brain Res; 2003 Behav Brain Res) in NMBR-deficient mice. The pain and itch role in dorsal spinal cord somatosensory neurons was developed by Fleming, Saxena, and Mishra in 2012 (J Neurosci), distinguishing NMB's role from GRP's primary spinal pruritogenic activity. The cancer thread runs in parallel through small-cell lung cancer (where bombesin-family peptides act as autocrine growth factors), prostate cancer (where GRPR is overexpressed and is a major target for radioligand imaging/therapy), and other tumors. Drug development around bombesin-receptor antagonists has produced multiple clinical-stage candidates over the decades, with limited clinical wins outside of radiolabeled imaging agents — primarily because of the breadth of bombesin-family physiology and the difficulty of selectively targeting one receptor subtype without on-target off-tissue effects. As of 2026, NMB remains a foundational endogenous peptide in the bombesin-family pharmacology with a well-characterized receptor (NMBR), defined physiological roles across smooth muscle, thyroid axis, thermoregulation, anxiety, pain/itch, and cancer, and active but incomplete drug-discovery interest. No NMB or NMBR-targeted therapeutic has reached approval.

How It Works

Neuromedin B is one of the body's two main 'bombesin-family' peptides — small signaling proteins related to bombesin, a peptide originally found in frog skin in the 1970s. Mammals make two such peptides: NMB (the short, 10-amino-acid form) and GRP (the longer 27-amino-acid form). They look similar at one end (the part that grabs the receptor) but engage different receptors and do different things. NMB squeezes smooth muscle (in your gut, bladder, and uterus), tells your pituitary how much TSH to release (which controls thyroid activity), drops body temperature when injected into the brain, and helps shape anxiety, satiety, and pain/itch processing. It works through a receptor called NMBR (also called BB1). The cancer-drug interest in this peptide family comes from the fact that small-cell lung cancers and prostate cancers cover themselves in bombesin receptors and use them as growth-factor signals — which is why drug developers have built bombesin-pathway antibodies and radiolabeled bombesin analogs as cancer treatments and imaging agents.

Neuromedin B is encoded by the NMB gene on human chromosome 15q25 — cloned and characterized by Krane, Naylor, Helin-Davis, Chin, and Spindel in 1988 (J Biol Chem). The gene encodes a 76-residue prepro-NMB precursor that is processed by signal-peptide cleavage and a single proteolytic step to release the mature 10-residue NMB peptide (Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2). The C-terminal His-Phe-Met-NH2 is the bombesin-family pharmacophore shared with GRP, the longer mammalian homolog, and with the prototype frog peptide bombesin itself. NMB is widely distributed in the central nervous system (notably in hypothalamus, brainstem, and dorsal spinal cord), in the gastrointestinal tract, in thyroid tissue, and in dorsal root ganglion sensory neurons. NMB signals primarily through the neuromedin B receptor (NMBR, also designated bombesin receptor subtype 1 or BB1), a class-A rhodopsin-family GPCR cloned by Wada, Way, Lebacq-Verheyden, and Battey from rat brain in 1991 (J Biol Chem). NMBR couples to Gq/11, activating phospholipase C, mobilizing intracellular calcium, and producing IP3-mediated signaling characteristic of class-A peptide-activated GPCRs. NMBR has approximately 100-fold higher affinity for NMB than for GRP, and its tissue distribution differs from GRPR — NMBR is enriched in CNS (hypothalamus, brainstem, dorsal spinal cord), thyroid, esophagus, and certain breast tissue, while GRPR is more prominent in pancreas, gut, brain limbic regions, and prostate. The third bombesin family receptor, BRS-3 (BB3), is an orphan with low affinity for both NMB and GRP whose endogenous ligand identity is still debated. The 2008 Jensen, Battey, Spindel, and Benya IUPHAR review provides the standard contemporary nomenclature and pharmacology. Functionally, NMB contributes to multiple physiological systems. (1) Smooth muscle: NMB produces contraction of gastrointestinal, urinary, and uterine smooth muscle — the classical bombesin-family activity. (2) Endocrine: hypothalamic NMB modulates the pituitary-thyroid axis. NMBR knockout mice (Oliveira, Costa, and colleagues 2006) show dysregulated TSH secretion, increased anterior pituitary TSH content, and altered thyroid hormone homeostasis, formally establishing NMB as a hypothalamic regulator of thyroid function. (3) Thermoregulation: central NMB administration produces hypothermia in rats, an effect characterized by Vergoni and Bertolini in the 1980s and 1990s (1995 Eur J Pharmacol on neuromedins and body temperature). (4) Anxiety and emotional behavior: Yamada and colleagues (2002 Brain Res; 2003 Behav Brain Res) showed that NMBR-deficient mice have stress-induced impairment of inhibitory avoidance learning and altered emotional behavior in standard paradigms, complementing GRPR knockout phenotypes (which show altered fear conditioning) and indicating that the two bombesin receptors contribute distinct components to emotional processing. (5) Pain and itch: the 2012 Fleming, Saxena, Mishra paper showed that NMB is highly expressed in pain- and itch-sensing somatosensory neurons of the dorsal spinal cord, distinguishing NMB's role from GRP's well-established role as a primary spinal pruritogen. (6) Cancer: although less prominent than GRPR in tumor biology, NMBR is expressed on certain breast, esophageal, and other tumors, and bombesin-family peptides serve as autocrine growth factors in small-cell lung cancer (Kelley 1991 NCI; subsequent literature). Drug development around the bombesin family has been pursued for decades but has produced limited clinical wins outside of radiolabeled imaging agents. Bombesin-receptor antagonists (RC-3095, BIM-26226, and others) have been characterized as research tools and tested in early-phase oncology trials. Radiolabeled bombesin analogs targeting GRPR — particularly Lu-177 and Ga-68 conjugates — have been developed for prostate cancer imaging and therapy, with several candidates in active clinical development. NMBR-selective ligands have been characterized but have not produced approved drugs. The translational space remains active but unresolved.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Neuromedin B:

• 01Whether selective NMBR agonists or antagonists will produce approved therapeutics for any indication — four decades of preclinical biology has not yet translated into approved drugs.
• 02Whether bombesin-receptor radioligand therapy (currently focused on GRPR for prostate cancer) will expand to NMBR-targeted theranostics for breast, esophageal, or other cancers with NMBR expression.
• 03The functional contribution of NMBR signaling to specific human anxiety, stress, and emotional-behavior phenotypes, given the rodent knockout findings.
• 04Whether NMB-pathway modulation has therapeutic potential in pruritus, given NMB's expression in dorsal-spinal-cord pain- and itch-sensing somatosensory neurons.
• 05The relative contribution of central versus peripheral NMB to the pituitary-thyroid axis regulation seen in NMBR knockout mice, and whether this could inform thyroid-axis therapeutic strategies.
• 06The endogenous ligand identity for the orphan BRS-3 receptor — a long-standing open question that affects how the bombesin-family receptor system is understood as a whole.
• 07Whether dual NMBR/GRPR antagonism would be therapeutically superior to selective single-receptor antagonism in cancer or in pruritus indications.

Forms & Administration

NMB is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic NMB-10 for in vitro NMBR binding and signaling assays, ex vivo smooth-muscle contraction studies, and intracerebroventricular, intrathecal, intraperitoneal, or intravenous administration in animal models. Selective NMBR agonists and antagonists exist as research tools. Bombesin-receptor radioligand conjugates (Lu-177, Ga-68 labeled bombesin analogs) are clinical-stage agents for prostate cancer imaging and therapy, but these target GRPR more than NMBR. Compounded NMB from peptide-marketplace channels has no validated clinical use.

Common Questions

Who Neuromedin B Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for NMB because no NMB product has been clinically developed. Theoretical interactions follow from documented signaling. Smooth-muscle effects could in principle interact with prokinetic agents (metoclopramide, prucalopride), motilin agonists (erythromycin), uterine-tone modulators, and bladder-active drugs. Pituitary-thyroid-axis effects could interact with thyroid hormone replacement (levothyroxine) and antithyroid medications (methimazole, propylthiouracil). Bombesin-receptor antagonist drugs in development for cancer and pruritus could be pharmacodynamically opposed by exogenous NMB. None of these interactions has been characterized in controlled human studies.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions